The Oncologist: Patient Conversation Must Include Clinical Trials
Dr. Shalaan Beg, VP of Oncology for Science 37, discusses his approach to reducing the time to trial activation at an NCI designated cancer center, how to ensure a diverse representation in clinical trials, and his opinion on decentralized and hybrid trials.
This podcast sponosored by LabVantage Soultions
Related Content
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025Podcast
In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
